Nanocarry is developing a new class of therapeutics for brain cancers and CNS diseases based on a proprietary technology platform of insulin-based bioengineered nanoparticles that offers infinite possibilities for optimal modalities and mechanisms of action to treat brain diseases.
The AxS platform is poised to solve the biggest challenge in the field of brain therapeutics, by enabling the delivery of biologics across the blood brain barrier in a simple and traceable manner. It pioneers a therapeutic approach, converging the biological process of receptor-mediated transcytosis (RMT) with bioengineered nanoparticles (NPs). The AxS platform’s capabilities can be rapidly adjusted for the creation of multiple therapeutics across many brain diseases. AxS brain-targeted delivery can be quantified and traced, in a clinical setting, in real time, verifying that the therapeutic reaches the brain.
The AxS platform is an insulin-based BBB-crossing technology that utilizes bioengineered nanoparticles (NPs) with unique physical and optical properties, enabling targeted delivery and a broad range of biological, chemical, and medical applications. AxS novel structure overcomes the stability limitations that have prevented previous insulin-based delivery approaches.
The surface of NPs have a strong binding affinity which allows for surface conjugation with various peptides, proteins, antibodies, and other biomolecules. These surface modifications expand the applications by enabling them to target specific sites on the cell surface, organelles or the extracellular matrix and serve as “smart” drug carriers.
NPs can be tracked noninvasively using advanced imaging modalities, leveraging their unique physicochemical properties, and can be quantitatively detected ex vivo using analytical techniques. In vivo imaging of the AxS platform enables precise assessment of nanoparticle delivery to specific brain regions associated with neurodegenerative and neuropsychiatric disorders.
During over a decade of research at Prof. Popovtzer’s Nanoparticles lab, the AxS technology platform was developed and perfected into an efficient gold nanoparticle-based system that can overcome the restrictive mechanism of the BBB. The platform was extensively studied in healthy animal models as well as in neurodegenerative disease models and brain tumors.
Nanocarry’s AxS platform can be used to develop a wide array of brain therapeutics, such as antibodies, peptides and other biologics and small molecules with low brain bioavailability. Its unique advantages stem from its convergence of biology and nanotechnology, and include:
One-core technology allows for multiple product generation and a replicable manufacturing process
>100-fold increase in NHP brain
20–40-fold increase in rodent models
Enhanced drug stability and less off-target due to particle retention within the bloodstream
Generate multi-specific particles enabling new mechanisms of action
Targeting capabilities on the cell surface, organelles, or extracellular matrix
NPs can be traced noninvasively using CT imaging & quantified ex vivo by atomic absorption methods
